Targeting Btk In Relapsedrefractory Mzl
Using Ibrutinib in Relapsed/Refractory MZL
2:48
Targeting BTK and Bcl-2 for B-Cell Malignancies: Where Are We Moving Toward?
21:28
Targeting BTK in B-Cell Malignancies
3:53
Ibrutinib As Second-Line Therapy in Refractory MZL
2:15
Case Overview: Advanced MZL With Disease Progression
4:12
MZL: Managing Patients Who Receive Ibrutinib
4:10
Dr. Leslie on the Role of BTK Inhibitors in Relapsed/Refractory MCL
1:47
Solving the Puzzles for B-Cell Malignancies: Navigating the Place of BTK Inhibitors Today and Tom...
1:32:21
BTK Inhibition in Relapsed/Refractory CLL
2:45
BTK Inhibitors in Other B-cell Lymphomas
4:42
Progress With BTK Inhibitors: A Journey Through the Mechanisms of Covalent and Noncovalent Options
22:36
BTK inhibitor With vs Without a CD20-Targeted Antibody
7:29
TG-1701: a BTK inhibitor for B-cell malignancies
4:25
BTK Inhibitors: Infections and Secondary Malignancies
4:44
Pirtobrutinib Non-Covalent BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - BRUIN Study
8:55
BTK Inhibitors Explored in B-Cell Malignancies
4:40
discovery of PRN1008, a BTK inhibitor - drug annotations
19:02
BTK Inhibitors and Toxicity Management in B-Cell Lymphomas
7:59
Recent searches
